Anthem Blue Cross cancels rate hike, but BCBS New Mexico wins approval; FDA probes prostate meds for diabetes, heart risks;

> The share prices of WellPoint, UnitedHealth Group, Aetna and Cigna fell from 3 percent to 9 percent on April 30 just days after many of those same insurers posted significant earnings gains for the first quarter of fiscal year 2010. The problem: Investor concerns about future profits in the face of contentious rate hikes. FierceHealthPayer

> The FDA announced that it's reviewing the safety of a class of prostate cancer drugs, following up on data that suggest an increased risk of diabetes and certain heart problems. FiercePharma

> Overwhelmingly strong iPad sales in the U.S. have prompted Apple to delay the product's introduction in foreign markets, but that hasn't stopped health IT reporters in other countries from licking their chops, too. FierceMobileHealthcare

And Finally... Robin Hood this guy is not. Article